Thromboembolic and bleeding events after valvular intervention in patients with atrial fibrillation

Figure 1. Description of the study cohorts. AF, atrial fibrillation; TAVI, transcatheter aortic valve implantation.

Figure 2. Cumulative event rate for the composite CV outcome (CV death, ischaemic stroke or systemic embolism (SE)); ischaemic stroke or SE; CV death and major bleeding during the first 3 months after discharge from valvular intervention for patients treated with warfarin, NOAC or no OAC. CV death, cardiovascular death; NOAC, non-vitamin K antagonist oral anticoagulant; No at risk, number at risk; OAC, oral anticoagulant; SE, systemic embolism.

Figure 3. Cumulative event rate for the composite CV outcome (CV death, ischaemic stroke or systemic embolism (SE)); ischaemic stroke or SE; CV death and major bleeding from 3 to 12 months after valvular intervention separated by warfarin, NOAC or no OAC exposure. CV death, cardiovascular death; NOAC, non-vitamin K antagonist oral anticoagulant; No at risk, number at risk; OAC, oral anticoagulant; SE, systemic embolism.

Figure 4. The event rates of the composite CV outcome (CV death, ischaemic stroke or systemic embolism (SE)); ischaemic stroke or SE; CV death and major bleeding, and HR (95% CI) for NOAC versus warfarin and no OAC versus warfarin during the first 3 months after discharge from valvular intervention. The adjusted model included baseline characteristics and comorbidities. %/year, per cent per PY; CV death, cardiovascular death; HR-adj, HR adjusted; HR-unadj, HR unadjusted; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; PY, patient years; SE, systemic embolism.

Figure 5. The event rates of the composite CV outcome (CV death, ischaemic stroke or systemic embolism (SE)); ischaemic stroke or SE; CV death and major bleeding, and HR (95% CI) for NOAC versus warfarin and no OAC versus warfarin from 3 to 12 months after the valvular intervention. The adjusted model included baseline characteristics and comorbidities. %/year, per cent per PY; CV death, cardiovascular death; HR-adj, HR adjusted; HR-unadj, HR unadjusted; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; PY, patient years; SE, systemic embolism.